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PPeripheral Vascular Disease
Novel Cardiovascular Risk Factors Do Not
Completely Explain the Higher Prevalence of
Peripheral Arterial Disease Among African Americans
The San Diego Population Study
Joachim H. Ix, MD, MAS,*†‡ Matthew A. Allison, MD, MPH,‡ Julie O. Denenberg, MA,‡
Mary Cushman, MD,§ Michael H. Criqui, MD, MPH*‡
San Diego, California; and Burlington, Vermont
Objectives This study was designed to determine whether novel cardiovascular disease (CVD) risk factors explain the high
prevalence of peripheral arterial disease (PAD) among African Americans.
Background Compared with Caucasians, African Americans have higher prevalence of PAD, an association that is not ex-
plained by traditional CVD risk factors. The degree to which novel CVD risk markers may explain the higher prev-
alence is uncertain.
Methods A nested case-control study within the San Diego Population Study was performed. The study evaluated 104 per-
sons with PAD and 164 age- and gender-matched control subjects who were employees of a large public univer-
sity and participated in a peripheral artery and venous disease study. Nine novel CVD risk factors (homocysteine,
lipoprotein (a), C-reactive protein, fibrinogen, tumor necrosis factor-alpha, von Willebrand factor, prothrombin
fragment 1-2, D-dimer, and plasmin antiplasmin) were measured. Multivariable logistic regression evaluated
whether these novel factors attenuated the association of African-American race and PAD and whether there
was differential ethnic susceptibility to the novel factors.
Results African Americans had 3-fold higher odds of PAD in age- and gender-matched models (odds ratio [OR] 3.1; 95%
confidence interval [CI] 1.5 to 6.4; p  0.01), an association that was modestly attenuated by adjustment for
traditional (OR 2.4; 95% CI 0.9 to 6.1; p  0.06) and novel CVD risk markers (OR 1.9; 95% CI 0.7 to 4.7; p 
0.18). Among the novel factors, the attenuation was primarily due to fibrinogen and lipoprotein (a). No interac-
tions by novel CVD risk markers (both p values for interaction 0.24) were observed.
Conclusions Traditional and novel CVD risk factors only partially explain the higher prevalence of PAD among African
Americans. (J Am Coll Cardiol 2008;51:2347–54) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.022r
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wrior studies have consistently demonstrated higher preva-
ence of peripheral arterial disease (PAD) among African
mericans compared to Caucasians (1–6). Although Afri-
an Americans have a higher prevalence of traditional
ardiovascular disease (CVD) risk markers such as diabetes
nd hypertension, the racial difference in PAD prevalence
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Manuscript received January 9, 2008; revised manuscript received February 15,
008, accepted March 17, 2008.emains independent and is only modestly attenuated by
djustment for these traditional CVD risk markers (1).
Recently, several novel CVD risk markers have been
dentified (7), and these provide insight into distinct bio-
ogic pathways contributing to CVD. Compared with Cau-
asians, African Americans have been shown to have dif-
erent concentrations of several of these risk markers in prior
esearch (8,9). Whether or not higher or lower concentra-
ions of these factors may explain the association of African-
merican race with PAD has not been extensively studied
8,10).
We hypothesized that the higher prevalence of PAD among
frican Americans would be at least partially accounted for by
ovel CVD risk markers. Therefore, we identified 9 serum
isk markers that had been associated with PAD and that
ere reported to have different serum concentrationsmong African Americans compared with Caucasians
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Race, PAD, Novel Risk Factors June 17, 2008:2347–54in prior literature: homocysteine,
lipoprotein (a), C-reactive pro-
tein, fibrinogen, tumor necrosis
factor-alpha, von Willebrand
factor, prothrombin fragment
1-2, D-dimer, and plasmin an-
tiplasmin. We measured these
markers in the San Diego Pop-
ulation Study—an ethnically di-
verse study sample with detailed
measurements of arterial disease—
and we evaluate whether these
novel CVD risk markers attenu-
ated the association of African-
American race with PAD.
ethods
ubjects. Current and retired employees of the University
f California, San Diego and their spouses or significant
thers were invited to participate in a study focused on both
eripheral arterial and venous disease. Methods of recruit-
ent and response rates have previously been reported (11).
riefly, random selection was made within strata defined by
ge, gender, and race/ethnicity. Women and race/ethnic
inority groups were oversampled to enhance power for
ontrasts between groups. The total sample size was 2,414
ubjects and all provided written informed consent after a
etailed study description. The study was approved by the
ommittee on Investigations Involving Human Subjects at
niversity of California, San Diego.
The present study was a nested case-control study. All
articipants underwent a detailed vascular examination that
ncluded ankle-brachial index (ABI) measurement (de-
cribed in the following sections). From this, we identified
04 persons with PAD. We selected 164 participants
ithout PAD as control subjects, who were frequency
atched to cases on the basis of age and gender.
emographic and clinical measurements. At the study
isit, participants were interviewed by trained study person-
el for demographic and medical history information, in-
luding age, gender, race/ethnicity, education, occupation,
ast personal and family medical history, and medication
se. History of CVD was defined as past history of
yocardial infarction, percutaneous transluminal coronary
ngioplasty, coronary artery bypass graft surgery, stroke, or
ransient ischemic attack. Diabetes was defined by medical
istory. Current and past smoking history was ascertained,
nd pack-years were calculated. Hypertension was defined
s a systolic blood pressure (SBP) 140 mm Hg, diastolic
lood pressure 90 mm Hg, or use of antihypertensive
edications. Hyperlipidemia was defined by a total/high-
ensity lipoprotein cholesterol ratio 6.4 in men and 5.6
n women (a threshold previously demonstrated to provide
ptimal risk prediction for CVD events) (12) or use of
Abbreviations
and Acronyms
ABI  ankle-brachial index
BMI  body mass index
CVD  cardiovascular
disease
CV  coefficient of
variation
ELISA  enzyme-linked
immunosorbent assay
PAD  peripheral arterial
disease
SBP  systolic blood
pressure
WHR  waist/hip ratioipid-lowering medications. waboratory measurements. At the study visit, venous sam-
les were drawn, and homocysteine was measured by a
uorescence polarization immunoassay (IMx Homocysteine
ssay, Axis Biochemicals, Oslo, Norway) using the IMx
nalyzer (Abbott Diagnostics, Abbott Park, Illinois). The
ntra- and interassay coefficients of variation (CVs) were
5%. Lipoprotein (a) was measured using an enzyme-
inked immunosorbent assay (ELISA) developed at the
niversity of Vermont and described elsewhere (13). The
Vs were 8%. High-sensitivity C-reactive protein was
easured using a particle-enhanced immunoturbidimetric
ssay on a BN-II analyzer (Dade-Behring Inc., Deerfield,
llinois) with CVs 4%. Fibrinogen was measured in an
utomated clot rate assay based upon the Clauss method
14) using the STA-R instrument (Diagnostica Stago,
snières sur Seine) with CVs 4%. Tumor necrosis factor-
lpha assays also employed a Quantikine ELISA assay (R &
Systems, Minneapolis, Minnesota) with an intra-assay
V of 5.9% and interassay CV of 12.6%. The von Wille-
rand factor was measured with an immunoturbidimetric
ssay (Liatest vWF, Stago) on the STA-R analyzer (Stago),
hereby latex particles agglutinate in the presence of the
on Willebrand factor and increase light absorbance in
roportion to its concentration. The CVs were 5%.
rothrombin fragment 1–2 was measured using ELISA
Dade-Behring), and the CVs were 12% (15). The
-dimer measurement also used the Stago immunoturbi-
imetric assay with CVs 5%. Lastly, the plasminogen-
ntiplasmin measurement was performed using a 2-site
LISA that detects only complex, and not free, plasmin or
ntiplasmin (16). The CVs were 4%.
AD measurement. Subjects underwent a detailed vascu-
ar examination at the study visit. Briefly, with the subjects
ying supine and using a continuous-wave Doppler, SBP
as measured in both brachial arteries, and twice in both
osterior tibial arteries. When a signal could not be found at
he posterior tibial artery, the dorsalis pedis artery was
nsonated in the same manner. The ABI for each leg was
alculated as the average SBP in the posterior tibial (or
orsalis pedis) artery divided by the higher of the 2 arm
BPs. A PAD was defined as an ABI 0.90, an abnormal
oppler waveform (no negative component and broad-
ned), or previous history of revascularization for PAD.
tatistical analysis. We evaluated differences in demo-
raphic and clinical data among cases and control subjects
y the t test for continuous variables (or Mann-Whitney
ank sum test for variables with skewed distributions) and
hi-square tests (or Fisher exact test equivalent) for categor-
cal variables. Similarly, we evaluated differences in serum
oncentrations of the 9 novel risk markers across racial
roups. After log-transformation of skewed variables, a
earson correlation matrix determined that none of the 9
ovel factors were highly correlated with one another
highest r  0.20), thereby allowing multiple adjustment
ithout significant colinearity.
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June 17, 2008:2347–54 Race, PAD, Novel Risk FactorsMaximum likelihood logistic regression analysis evalu-
ted the associations of race and PAD in 4 separate models.
odel 1 was age and gender matched. Model 2 adjusted for
mportant demographics (education and occupation) and
raditional cardiovascular risk factors identified, in a prior
anuscript (1), as correlates of PAD in this cohort (age,
ender, race/ethnicity, diabetes, hypertension, hyperlipid-
mia, prevalent CVD history, and tobacco use). In explor-
tory analyses, we observed an inverse association of body
ass index (BMI) with PAD, consistent with prior studies
1,3,17–21), but observed a direct association of waist/hip
atio (WHR) with PAD. Recent large observational studies
22,23) have demonstrated that WHR is more strongly
ssociated with future CVD events than BMI. Therefore,
e elected to adjust for WHR rather than BMI within
odel 2. In Model 3, we selected covariates from the 9
ovel biomarkers if they were associated with both African-
merican race and PAD. Because relatively weak associa-
ions may contribute substantial confounding effects (24),
ny variable associated with both African-American race
nd PAD with a p value 0.25 was included in this model,
n addition to variables that were included in Model 2.
kewed variables were log-transformed, and results are
resented as 1 standard deviation increase in each, to allow
omparison of strength of association across novel risk
arkers. Lastly, to develop a most parsimonious model,
odel 4 excluded all covariates where the p value for
ssociation with PAD was 0.25 in Model 3. For each
ovel marker retained in Model 4, multiplicative interaction
erms were created (marker  race/ethnicity) and individ-
ally added to Model 4. These interaction terms allowed
xploration of the possibility of differential ethnic suscepti-
ility to risk markers. The area under the receiver operator
urve were calculated for each model and compared to the
receding model by determination of the c-statistic. Models
ere also evaluated for goodness of fit by the Hosmer-
emeshow statistic, and graphical methods evaluated the
ssumptions of linear relationships between continuous
redictors and log-odds of PAD. No violations were ob-
erved. Lastly, we compared the percent attenuation in the
dds of PAD among African Americans compared with
aucasians after adjustment for traditional and novel CVD
isk factors observed in our manuscript to those reported
reviously. Because the baseline odds ratio would be 1.0 if
he association was completely attenuated, we subtracted 1.0
rom the odds ratio both before and after adjustment,
etermined their ratio, and subtracted this ratio from 1.
wo-tailed p  0.05 was considered statistically significant.
nalyses were performed using STATA version 9.2 (Stata
orp., College Station, Texas).
esults
he 268-person study sample had a mean age of 69 years
nd was 53% female. Seventy percent were Caucasian, 15%
ere African American, 9% were Hispanic, and 6% were nsian. African Americans had less frequently attained a
ollege education; were less likely to have an administrative,
echnical, or professional occupation; and more frequently
ad diabetes, hypertension, and larger BMI, as demon-
trated previously (1). We observed 104 cases of PAD (4.4%
f the parent study sample). In persons with PAD, the
verage ABI was 0.78 in men and 0.82 in women. Seven
ubjects (7%) were categorized as PAD cases on the basis of
istory of prior revascularization. Age and gender were
alanced across PAD groups, reflecting the matched study
esign (Table 1). Persons with PAD were more frequently
frican American and less likely to have graduated from
ollege or to have worked in a technical, administrative, or
rofessional position. In addition, PAD cases had higher
revalence of diabetes, hypertension, hyperlipidemia, prev-
lent CVD, cumulative pack-years of tobacco use, and had
igher WHR. The PAD cases also had significantly higher
omocysteine, lipoprotein (a), fibrinogen, von Willebrand
actor, D-dimer, and plasmin antiplasmin levels; whereas
-reactive protein, tumor necrosis factor-alpha, and pro-
hrombin fragment 1-2 did not differ significantly across
AD groups.
Table 2 shows the concentrations of the 9 novel CVD
isk markers by African-American or Caucasian race. Afri-
an Americans had higher lipoprotein (a), fibrinogen, von
illebrand factor, and D-dimer concentrations in age- and
ender-adjusted models. Median C-reactive protein con-
entrations were higher and prothrombin fragment 1-2
ere lower in African Americans; these associations were of
orderline statistical significance (p  0.12 and 0.13,
espectively).
In univariate analysis, African Americans had greater than
-fold odds of PAD compared with Caucasians (Table 3).
djustment for traditional CVD risk markers attenuated
he association by 33% but African Americans remained at
.4-fold higher odds of PAD (Model 2 in Table 3). In the
ext model (Model 3), we included novel risk markers if
hey were at least weakly associated (p  0.25) with both
frican American race and PAD in univariate analysis
lipoprotein (a), C-reactive protein, fibrinogen, von Wille-
rand factor, and D-dimer). With their inclusion, the odds
f PAD among African Americans was attenuated an
dditional 36%. Thus, traditional and novel CVD risk
actors collectively attenuated the association by 57%, but
frican Americans remained at approximately 2-fold higher
dds of PAD compared to Caucasians (Model 3 in Table 3).
ast, we developed a parsimonious model that retained only
hose variables that were at least modestly associated with
AD (p  0.25) within Model 3. Among the novel CVD
isk markers, only lipoprotein (a), C-reactive protein, and
brinogen were retained by this inclusion criterion. In this
odel, African Americans remained at nearly 2-fold odds of
AD compared to Caucasians (Model 4 in Table 3). We
bserved no evidence of effect modification by any of the 3
ovel risk factors (all p values for interaction 0.24), and
t
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Race, PAD, Novel Risk Factors June 17, 2008:2347–54hus no evidence of greater African-American susceptibility
o these novel markers.
iscussion
rior studies have consistently demonstrated a 3-fold higher
revalence of PAD among African Americans compared
ith Caucasians (1,3,4,8). Even though PAD is strongly
ssociated with traditional CVD risk markers (3,25), we
Baseline Characteristics by PAD Status
Table 1 Baseline Characteristics by PAD St
Demographics
Age (yrs),  SD
Female (%)
Race/ethnicity
Caucasian (%)
African American (%)
Hispanic (%)
Asian American (%)
College education
Technical, administrative, or professional occupation
Medical history
Diabetes (%)
Hypertension (%)
Hyperlipidemia (%)
Cardiovascular disease (%)
Pack-yrs of tobacco*
Measurements
Ankle-brachial index,  SD
Waist/hip ratio,  SD
Novel cardiovascular risk factors
Homocysteine (mol/l),  SD
Lipoprotein (a) (g/l)*
C-reactive protein (mg/l)*
Fibrinogen (mg/dl),  SD
Tumor necrosis factor-alpha (pg/ml),  SD
von Willebrand factor (%),  SD
Prothrombin fragment 1–2 (nmol/l)*
D-dimer (mg/l)*
Plasmin-antiplasmin (nmol/l),  SD
*Median (interquartile range) evaluated by the Mann-Whitney rank su
PAD  peripheral arterial disease.
Novel Cardiovascular Risk Factor Concentration
Table 2 Novel Cardiovascular Risk Factor C
African Am
(n  3
Homocysteine (mol/l),  SD 12.0 3
Lipoprotein (a) (g/l)† 0.3 (0.1,
C-reactive protein (mg/l)† 3.1 (1.1,
Fibrinogen (mg/dl),  SD 370 9
Tumor necrosis factor-alpha (pg/ml),  SD 2.4 1
von Willebrand factor (%),  SD 160 6
Prothrombin fragment 1–2 (nmol)† 2.1 (1.7,
D-dimer (mg/l)† 0.40 (0.21
Plasmin-antiplasmin (nmol/l),  SD 7.9 4*Evaluated by linear regression. Skewed variables (lipoprotein (a), C-reac
transformed. †Median (interquartile range) evaluated by the Mann-Whitney rreviously reported that these factors do not account for the
igher prevalence of PAD (1). African Americans have
ifferent blood levels of several novel markers; therefore, we
ypothesized that these factors may account for the higher
revalence of PAD (1,2). The present study demonstrates
hat the association of African-American race with PAD
as only partially attenuated by the 9 novel markers studied
nd that lipoprotein (a) and fibrinogen were the 2 factors
D (n  104) No PAD (n  164) p Value
69 10 68 9 0.37
55 (53) 87 (53) 0.98
0.01
69 (66) 120 (73)
25 (24) 14 (9)
6 (6) 18 (11)
4 (4) 12 (7)
38 (37) 97 (59) 0.01
59 (57) 119 (78) 0.01
26 (25) 7 (4) 0.001
82 (79) 98 (60) 0.01
35 (35) 33 (21) 0.01
33 (32) 10 (6) 0.001
10 (0, 44) 0 (0, 15) 0.001
.78 0.24 1.10 0.09 —
.91 0.09 0.88 0.08 0.01
2.4 4.9 11.0 3.5 0.01
.2 (0.1, 0.4) 0.1 (0.0, 0.3) 0.01
.9 (0.9, 4.8) 1.6 (0.8, 3.5) 0.22
349 88 332 62 0.001
2.3 1.2 2.2 1.0 0.55
155 58 135 55 0.01
.7 (2.0, 4.1) 2.6 (1.9, 4.1) 0.99
5 (0.22, 0.65) 0.26 (0.16, 0.47) 0.01
8.8 4.8 6.9 3.8 0.01
Race
ntrations by Race
Caucasian
(n  189) p Value
Age and Gender
Adjusted
p Value*
11.6 3.2 0.60 0.68
0.1 (0.1, 0.3) 0.001 0.01
1.6 (0.9, 3.9) 0.07 0.12
345 70 0.15 0.03
2.2 1.0 0.53 0.36
143 56 0.13 0.03
2.7 (2.0, 4.2) 0.02 0.13
0.28 (018, 0.47) 0.05 0.01
7.7 4.2 0.86 0.43atus
PA
0
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2
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June 17, 2008:2347–54 Race, PAD, Novel Risk Factorshat accounted for the attenuating effects. Collectively,
djustment for traditional and novel CVD risk markers
ttenuated the association by 57%. However, despite the
ttenuation, African Americans remained at nearly 2-fold
igher odds of PAD. There was no evidence for differ-
ntial ethnic susceptibility to the novel risk markers.
herefore, traditional and novel CVD risk markers only
artially account for the higher prevalence of PAD
mong African Americans, and the residual association
ultivariable Predictors of PAD
Table 3 Multivariable Predictors of PAD
Model 1*
PAD/total (n/N) 104/268
Demographics
Race/ethnicity
Caucasian Reference
African American 3.1 (1.5–6.4)
0.01
Hispanic 0.6 (0.2–1.5)
0.27
Asian American 0.6 (0.2–1.9)
0.36
College education
Technical, administrative, or professional occupation
Medical history
Diabetes
Hypertension
Hyperlipidemia
Cardiovascular disease
Pack-yrs tobacco (per 10 yrs)
Waist/hip ratio
Novel cardiovascular risk factors
Log-lipoprotein (a)
Log-C-reactive protein
Fibrinogen
von Willebrand factor
Log-D-dimer
Model diagnostics
Area under ROC curve, c-statistic 0.59
Hosmer-Lemeshow p value 1.00
Age- and gender-matched. †Adjusted for traditional cardiovascular risk factors. ‡Adjusted for Mod
n univariate analyses (Tables 1 and 2). §Covariates retained if p value for PAD was 0.25 in Mo
CI  confidence interval; OR  odds ratio; PAD  peripheral arterial disease; ROC  receiver-oemains unexplained. wTo the best of our knowledge, only 2 prior studies have
valuated the contribution of novel CVD risk markers to the
ssociation of African-American race with PAD. In the
ESA (Multi-Ethnic Study of Atherosclerosis), Allison
t al. (8) evaluated 9 novel CVD risk markers (homocys-
eine, C-reactive protein, interleukin-6, D-dimer, fibrino-
en, plasmin antiplasmin, factor VIII, von Willebrand
actor, and Chlamydia pneumoniae titer). Among these,
nterleukin-6 and fibrinogen were most strongly associated
OR (95% CI) p Value
Model 2† Model 3‡ Model 4§
98/246 92/227 92/234
Reference Reference Reference
2.4 (0.9–6.1) 1.9 (0.7–5.1) 1.9 (0.7–4.7)
0.06 0.21 0.18
0.4 (0.1–1.4) 0.5 (0.1–1.8) 0.6 (0.2–2.0)
0.16 0.28 0.40
1.4 (0.3–5.6) 1.2 (0.2–6.1) 1.3 (0.2–6.5)
0.64 0.87 0.79
0.7 (0.4–1.5) 0.6 (0.3–1.3) 0.6 (0.3–1.1)
0.40 0.23 0.11
0.6 (0.3–1.4) 0.7 (0.3–1.7)
0.23 0.45
5.9 (1.9–18.5) 3.7 (1.2–12.0) 3.6 (1.3–10.1)
0.01 0.3 0.02
2.1 (1.0–4.3) 2.1 (0.9–4.3) 1.8 (0.9–3.8)
0.04 0.06 0.10
1.6 (0.7–3.3) 1.4 (0.6–3.2)
0.23 0.37
4.9 (2.0–11.9) 4.2 (1.6–11.0) 5.4 (2.2–12.9)
0.01 0.01 0.01
1.2 (1.1–1.4) 1.2 (1.0–1.4) 1.1 (1.0–1.3)
0.01 0.02 0.04
0.6 (0.0–24.6) 1.2 (0.0–62.7)
0.80 0.93
1.4 (1.0–2.0) 1.4 (1.0–2.0)
0.06 0.06
0.8 (0.5–1.2) 0.8 (0.5–1.1)
0.25 0.17
1.5 (1.0–2.4) 1.7 (1.1–2.5)
0.04 0.01
0.97 (0.7–1.4)
0.86
1.2 (0.8–1.7)
0.35
0.79, 0.001¶ 0.81, 0.12# 0.80, 0.34#
0.62 0.35 0.36
riables and novel covariates selected if associated with PAD and African-American race (p 0.25)
Per standard deviation higher. ¶Compared with Model 1. #Compared with Model 2.
characteristic.el 2 vaith PAD in multivariable models. The novel factors
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Race, PAD, Novel Risk Factors June 17, 2008:2347–54rovided only a modest attenuation in the odds of PAD
mong African Americans (odds ratio decreased from 1.7 to
.5) (8). The investigators suggested that future studies
hould evaluate lipoprotein (a) (8). Indeed, lipoprotein (a)
evels are consistently 2-fold higher among African Amer-
cans (26,27), and have been associated with low ABI
28,29), symptomatic PAD (30), PAD severity (31), and
rogression (32). Moreover, lipoprotein (a) is potentially
odifiable (33,34).
Khawaja et al. (10) evaluated lipoprotein (a), fibrinogen,
-reactive protein, and homocysteine in the GENOA
Genetic Epidemiology Network of Arteriopathy) study.
fter adjustment for traditional CVD risk markers and
hese 4 novel measures, the investigators also observed a
odest attenuation in the odds of PAD among African
mericans (odds ratio 3.0 to 2.1). However, African-
merican race remained strongly associated with PAD (10).
ecause only these 4 novel measures were available, it was
ossible that the remaining association was due to other
nmeasured risk markers.
The present manuscript confirms the findings in these 2
rior studies and highlights the consistency among them.
lthough the 3 study samples differ in regards to age,
eography, prevalence of CVD and traditional CVD risk
arkers, each demonstrated that African-American race is
trongly associated with PAD. Moreover, the studies are
trikingly consistent in the magnitude of attenuation in the
oint estimates when adjusting for traditional and novel
VD risk markers, collectively resulting in 50% to 60%
ttenuation across the respective studies (Table 4). In each
f these studies, African Americans had roughly 2-fold
igher odds of PAD, despite extensive statistical adjustment
or both traditional and novel markers. Collectively, the
tudies provide consistent evidence that traditional and
ovel CVD risk markers do not completely explain the
igher prevalence of PAD among African Americans.
Why might African Americans have a higher preva-
ence of PAD? The association may reflect social differ-
nces or health care access disparities that are known to
e important risk factors for future CVD events (35).
tudy inclusion criteria required that participants (or
heir significant others) were current and former employ-
es of a large public university, and therefore, all had
ealthcare coverage. We have previously shown (1) that
rug treatment of hyperlipidemia was similar among
frican Americans and Caucasians in this study cohort
nd that drug treatment of hypertension was appropri-
dds Ratio of Peripheral Arterial Disease Among African Americans
Table 4 Odds Ratio of Peripheral Arterial Disease Among Africa
Allison et al. (8)
OR Attenua
Age- and gender-adjusted 2.3 —
Traditional cardiovascular risk factor adjusted 1.7 46%
Traditional and novel risk factor adjusted 1.5 62%Reflects weighted average of gender-specific odds ratios (ORs).tely more common in African Americans. Moreover, the
ssociation observed in this study remained, despite
djustment for education and occupation. Nonetheless, it
emains plausible that unmeasured sociodemographic
ariables such as diet, physical activity, income, and social
tress may account for these differences. Alternatively,
frican Americans may have greater genetic susceptibil-
ty to PAD (36). Recent advances in microarray technol-
gy and genetic epidemiology hold promise for evaluating
his important hypothesis, although such studies may be
articularly challenging among African Americans due to
heir higher degree of genetic diversity (37). Lastly, the
pectrum of vascular disease is different among African
mericans compared with Caucasians. African Ameri-
ans have lower prevalence of coronary artery calcification
38,39)—a highly sensitive marker for flow-limiting cor-
nary atherosclerotic disease (40)—and yet have higher
revalence of PAD. Whether racial differences exist in
echanisms leading to vascular disease or in genes that
odify proteins in the causal pathway should be evalu-
ted in future studies. Because the vascular disease
atterns are different in these racial groups, such studies
ay ultimately provide novel insights about vascular
isease biology globally and might also lead to race-
pecific screening modalities or therapies tailored for
aximum benefit within groups (41).
Although the results demonstrated here are in part
onfirmatory of prior studies, the present study has
everal advantages. First, it evaluated the largest number
f novel risk markers while simultaneously including
ipoprotein (a). Because lipoprotein (a) levels differ sub-
tantially among African Americans and Caucasians, are
trongly associated with PAD, and are potentially mod-
fiable, they represented a particularly important candi-
ate marker. Indeed, lipoprotein (a) was 1 of only 3 novel
isk factors that remained associated with PAD risk in
ultivariable models in our study. Second, our definition
f PAD included subjects with prior revascularization,
here other studies limited the definition to ABI mea-
urement in isolation. Because roughly 5% of prevalent
AD cases in the population are persons with prior
evascularization who may have normal ABIs (42), their
nclusion minimizes misclassification bias. Lastly, the
xistence of 2 prior studies allowed us to compare the
trength of association and attenuating effects of tradi-
ional and novel cardiovascular risk factors across studies.
pared With Caucasians Across Studies
ericans Compared With Caucasians Across Studies
Khawaja et al. (10)* Present Study
OR Attenuation OR Attenuation
3.1 — 3.1 —
2.9 10% 2.4 33%
2.0 52% 1.9 57%Com
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June 17, 2008:2347–54 Race, PAD, Novel Risk Factorstudy limitations. This study included relatively small
umbers of Hispanics or Asian Americans. However, the
ifferences in PAD prevalence in these race/ethnic groups
ompared to African Americans appear less pronounced (8).
lthough the relatively small sample size of this study
llowed us to efficiently evaluate a large number of novel
VD risk markers simultaneously, it limited statistical
ower resulting in nonstatistically significant associations in
djusted models. The precision of these estimates and the
argins of error should be considered when interpreting the
esults. Fortunately, the point estimates and degree of
ttenuation is highly consistent with prior studies as dem-
nstrated in Table 4. In addition, although this study
ncluded a large number of novel CVD risk markers
imultaneously, we cannot exclude confounding on the basis
f other unmeasured markers, imperfect ascertainment, or
easurement at 1 point in time.
onclusions
he dramatically higher prevalence of PAD among African
mericans is not completely explained by higher prevalence
f traditional CVD risk markers, by differences in 9 novel
VD risk markers evaluated in this study, or by increased
thnic susceptibility to these risk markers. This finding is
onsistent across studies. The etiology for the high preva-
ence of PAD among African Americans remains unex-
lained for now. Future studies should evaluate differences
n life-style factors and genetic determinants as possible
tiologies.
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